Cargando…

KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway

This study aimed to explore how kinesin family member 2C (KIF2C) influences the progression of non-small cell lung cancer (NSCLC). The levels of KIF2C and microRNA-186-3p (miR-186-3p) were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Through the utilization of cell countin...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Junmei, Zhang, Wei, Sun, Liping, Yu, Hongfang, Wang, Yuzhe, Feng, Li, Yang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160078/
https://www.ncbi.nlm.nih.gov/pubmed/37142638
http://dx.doi.org/10.1038/s41598-023-30073-5
_version_ 1785037209265504256
author Guo, Junmei
Zhang, Wei
Sun, Liping
Yu, Hongfang
Wang, Yuzhe
Feng, Li
Yang, Hao
author_facet Guo, Junmei
Zhang, Wei
Sun, Liping
Yu, Hongfang
Wang, Yuzhe
Feng, Li
Yang, Hao
author_sort Guo, Junmei
collection PubMed
description This study aimed to explore how kinesin family member 2C (KIF2C) influences the progression of non-small cell lung cancer (NSCLC). The levels of KIF2C and microRNA-186-3p (miR-186-3p) were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Through the utilization of cell counting kit-8 (CCK-8) assay, colony formation assay, wound closure assay, and Transwell assay, NSCLC cell proliferation, migration, and invasion were identified, respectively. NSCLC cell apoptosis was assessed using the TUNEL assay and flow cytometry (FCM) assay. Luciferase reporter analysis was used to investigate the relationship between KIF2C and miR-186-3p. Western blot assays were conducted to investigate the influence of KIF2C on the AKT-GSK3β-β-catenin pathway. The results showed that KIF2C was up‐regulated in NSCLC cells, which predicted poor prognosis. KIF2C overexpression promoted the proliferation, migration, and invasion of NSCLC cells as well as inhibited NSCLC cell apoptosis. KIF2C was as a key target of miR-186-3p. High expression of KIF2C, meanwhile, increased the levels of β-catenin, p-GSK-3β and phosphorylated protein kinase B (p-AKT). KIF2C downregulation and miR-186-3p upregulation reversed these outcomes. As an oncogenic factor, KIF2C is negatively regulated by miR-186-3p and participates in the progression of NSCLC through the AKT-GSK3β-β-catenin pathway.
format Online
Article
Text
id pubmed-10160078
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101600782023-05-06 KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway Guo, Junmei Zhang, Wei Sun, Liping Yu, Hongfang Wang, Yuzhe Feng, Li Yang, Hao Sci Rep Article This study aimed to explore how kinesin family member 2C (KIF2C) influences the progression of non-small cell lung cancer (NSCLC). The levels of KIF2C and microRNA-186-3p (miR-186-3p) were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Through the utilization of cell counting kit-8 (CCK-8) assay, colony formation assay, wound closure assay, and Transwell assay, NSCLC cell proliferation, migration, and invasion were identified, respectively. NSCLC cell apoptosis was assessed using the TUNEL assay and flow cytometry (FCM) assay. Luciferase reporter analysis was used to investigate the relationship between KIF2C and miR-186-3p. Western blot assays were conducted to investigate the influence of KIF2C on the AKT-GSK3β-β-catenin pathway. The results showed that KIF2C was up‐regulated in NSCLC cells, which predicted poor prognosis. KIF2C overexpression promoted the proliferation, migration, and invasion of NSCLC cells as well as inhibited NSCLC cell apoptosis. KIF2C was as a key target of miR-186-3p. High expression of KIF2C, meanwhile, increased the levels of β-catenin, p-GSK-3β and phosphorylated protein kinase B (p-AKT). KIF2C downregulation and miR-186-3p upregulation reversed these outcomes. As an oncogenic factor, KIF2C is negatively regulated by miR-186-3p and participates in the progression of NSCLC through the AKT-GSK3β-β-catenin pathway. Nature Publishing Group UK 2023-05-04 /pmc/articles/PMC10160078/ /pubmed/37142638 http://dx.doi.org/10.1038/s41598-023-30073-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Guo, Junmei
Zhang, Wei
Sun, Liping
Yu, Hongfang
Wang, Yuzhe
Feng, Li
Yang, Hao
KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway
title KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway
title_full KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway
title_fullStr KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway
title_full_unstemmed KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway
title_short KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway
title_sort kif2c accelerates the development of non-small cell lung cancer and is suppressed by mir-186-3p via the akt-gsk3β-β-catenin pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160078/
https://www.ncbi.nlm.nih.gov/pubmed/37142638
http://dx.doi.org/10.1038/s41598-023-30073-5
work_keys_str_mv AT guojunmei kif2cacceleratesthedevelopmentofnonsmallcelllungcancerandissuppressedbymir1863pviatheaktgsk3bbcateninpathway
AT zhangwei kif2cacceleratesthedevelopmentofnonsmallcelllungcancerandissuppressedbymir1863pviatheaktgsk3bbcateninpathway
AT sunliping kif2cacceleratesthedevelopmentofnonsmallcelllungcancerandissuppressedbymir1863pviatheaktgsk3bbcateninpathway
AT yuhongfang kif2cacceleratesthedevelopmentofnonsmallcelllungcancerandissuppressedbymir1863pviatheaktgsk3bbcateninpathway
AT wangyuzhe kif2cacceleratesthedevelopmentofnonsmallcelllungcancerandissuppressedbymir1863pviatheaktgsk3bbcateninpathway
AT fengli kif2cacceleratesthedevelopmentofnonsmallcelllungcancerandissuppressedbymir1863pviatheaktgsk3bbcateninpathway
AT yanghao kif2cacceleratesthedevelopmentofnonsmallcelllungcancerandissuppressedbymir1863pviatheaktgsk3bbcateninpathway